| Autor: |
Kumari, Vasantha, V. A., Ramya, V., Rajapriya |
| Předmět: |
|
| Zdroj: |
Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research); 2024, Vol. 15 Issue 8, p129-136, 8p |
| Abstrakt: |
INTRODUCTION : Mifepristone (RU 486) is a progesterone receptor modulator with antagonistic properties. It binds strongly to endometrial progesterone receptors, minimally to estrogen receptors, and upregulates androgen receptors. In a placebo-controlled trial low dose mifepristone (RU 486) has been shown to decrease myoma size as well as symptoms. An increase in androgen receptors also contributes to antiproliferative effects. Mifepristone also delays or inhibits ovulation, which may produce amenorrhoea. Direct suppressive effects on endometrial vasculature as well as on reducing stromal vascular endothelial growth factor (VEGF) have also been suggested for reducing menstrual blood loss. OBJECTIVES : To determine the efficacy and safety of mifepristone for the management of uterine fibroids in premenopausal women. MATERIAL AND METHODS : The study was conducted in the tertiary care center. This hospital-based study was conducted between September 2023 and February 2024 for 6 months. 30 consecutive cases were studied based on inclusion criteria. All patients were treated with mifepristone 25mg once daily for 3 months. A pictorial blood loss assessment chart (PBAC) score was used to assess menstrual blood loss. A haemogram, liver function test, and ultrasound were performed. RESULTS: In this study, we observed there was a significant improvement in the hemoglobin (Hb)level, a significant reduction in uterine volume, fibroid size, and heavy menstrual bleeding. CONCLUSION : Mifepristone was able to significantly improve the patient outcome by reducing the amount of blood flow during menstruation increasing the Hb levels and significantly reducing the size of myoma. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
